Wang Xue-mei, Fu Hong, Liu Geng-xin, Zhu Wei, Li Li, Yang Jin-xia
Department of Integrated Chinese and Western Medicine of Peking University First Hospital, Beijing, 100034, China.
Chin J Integr Med. 2007 Dec;13(4):258-63. doi: 10.1007/s11655-007-0258-7.
To observe the effects of modified Wuzi Yanzong Granule (WYG) on memory function and the activity of serum superoxide dismutase (SOD), malondialdehyde (MDA) levels, leukocyte mitochondrial DNA (mtDNA) deletion rate and beta-amyloid protein(1-28) (A beta(1-28)) in patients with mild cognitive impairment (MCI).
Thirty-six patients with MCI were selected based on the internationally recognized Petersen's criteria, and equally and randomly assigned to two groups. The treated group was treated with WYG and the control group was treated with placebo for 3 months. In addition, 20 healthy subjects were included in the study as the normal control group. Changes of memory function, SOD activity, MDA content, leukocyte mtDNA deletion rate and A beta(1-28) content were observed before and after treatment.
Compared with the normal control group, the memory quotient and SOD activity in patients with MCI decreased significantly (P < 0.01), while MDA, A beta(1-28) levels and the leukocyte mtDNA deletion rate increased significantly (P < 0.01). After treatment, levels of memory quotient and serum SOD activity increased while the serum MDA level, leukocyte mtDNA deletion rate and A beta(1-28) level decreased in the treated group compared with those before treatment (P<0.01, P<0.05). Meanwhile, leukocyte mtDNA deletion rate and A beta(1-28) content in the treated group were all lower than those in the control group (P<0.05).
WYG could improve memory function in patients with MCI and the therapeutic mechanism is possibly related to the increased activity of anti-oxidase, the improved free radical metabolism and the alleviation of leukocyte mtDNA oxidation damage. WYG shows clinical significance in delaying the progression of MCI.
观察改良五子衍宗颗粒（WYG）对轻度认知障碍（MCI）患者记忆功能、血清超氧化物歧化酶（SOD）活性、丙二醛（MDA）水平、白细胞线粒体DNA（mtDNA）缺失率及β-淀粉样蛋白（1-28）[Aβ（1-28）]的影响。
依据国际公认的彼得森标准选取36例MCI患者，将其平均随机分为两组。治疗组给予WYG治疗，对照组给予安慰剂治疗，疗程均为3个月。另外，纳入20名健康受试者作为正常对照组。观察治疗前后记忆功能、SOD活性、MDA含量、白细胞mtDNA缺失率及Aβ（1-28）含量的变化。
与正常对照组相比，MCI患者的记忆商数及SOD活性显著降低（P<0.01），而MDA、Aβ（1-28）水平及白细胞mtDNA缺失率显著升高（P<0.01）。治疗后，治疗组的记忆商数及血清SOD活性升高，而血清MDA水平、白细胞mtDNA缺失率及Aβ（1-28）水平较治疗前降低（P<0.01，P<0.05）。同时，治疗组的白细胞mtDNA缺失率及Aβ（1-28）含量均低于对照组（P<0.05）。
WYG可改善MCI患者的记忆功能，其治疗机制可能与抗氧化酶活性增强、自由基代谢改善及白细胞mtDNA氧化损伤减轻有关。WYG在延缓MCI进展方面具有临床意义。
